Intravitreal Aflibercept 8 mg Permits Longer Dosing Intervals in Patients With nvAMD

Objective: To compare clinical and safety outcomes of treatment of neovascular age-related macular degeneration (nvAMD) with aflibercept 8-mg intravitreal injections administered at 12- or 16-week intervals to that with aflibercept 2 mg administered at 8-week intervals. Design: Phase 3, randomized clinical trial. Participants/Methods: Previously untreated patients aged ≥50 years, diagnosed with active subfoveal nvAMD, were enrolled. Patients were randomized to 1 of 3 treatment groups. The first and second groups received aflibercept 8-mg injections monthly for 3 months, followed by 8-mg injections at 12- and 16-week intervals, respectively. The third group received aflibercept 2-mg injections monthly for 3 months, followed by 2-mg injections every 8 weeks. Follow-up assessments were completed that included measurement of visual acuity and repeat optical coherence tomography imaging. A standardized protocol based on the response to therapy was then implemented to extend the treatme more...